The novel anti-cancer molecule is expected to go into clinical trials by 2012 and both the companies will continue the collaboration in the development phase as well.
Endo will pursue development and commercialization of the compound, while Jubilant becomes eligible to receive development milestones.
The multi-target collaboration which began three years ago with a focus on differentiated therapies to address the unmet needs of cancer patient has delivered multiple milestones across the discovery phase.
Jubilant Global Drug Discovery and Development CEO and president Sri Mosur said the successful outcome is a result of the excellent collaboration between the scientists at Endo and Jubilant.